Acute Coronary Syndrome — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for acute coronary syndrome. 8 active patents protecting 1 drugs from 1+ originators. First major cliff: 2030. Daily refresh.

1
Approved drugs
8
Active US patents
61/100
Avg vulnerability
$1.1B
Annual revenue covered

Originators in Acute Coronary Syndrome

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

AstraZeneca 8 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating acute coronary syndrome. Each bar = one year. Y-axis scaled to peak year (4 patents).

4
30
4
36

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Brilinta
ticagrelor
 AstraZeneca 8 61 $1.1B 2030-04-17

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8425934 Brilinta other 68 2030-10-17
8425934 Brilinta other 68 2030-10-17
10300065 Brilinta method of use 62 2036-01-27
10300065 Brilinta method of use 62 2036-01-27
10300065 Brilinta other 62 2036-07-27
10300065 Brilinta other 62 2036-07-27
8425934 Brilinta formulation 53 2030-04-17
8425934 Brilinta formulation 48 2030-04-17

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
8425934 Brilinta formulation 48 2030-04-17
8425934 Brilinta formulation 53 2030-04-17
10300065 Brilinta other 62 2036-07-27
10300065 Brilinta other 62 2036-07-27
10300065 Brilinta method of use 62 2036-01-27
10300065 Brilinta method of use 62 2036-01-27
8425934 Brilinta other 68 2030-10-17
8425934 Brilinta other 68 2030-10-17

Related